TransMedics Group, Inc. TMDX
92.01 USD +1.07 (+1.17%)
At closeNov 11, 2026, 7:24 PM EST
91.48 -0.53 -0.58%
After hours · Nov 11, 7:24 PM ET
90.00 Day range 93.45
62.04 52-week range 150.42
- YTD
- -24.36%
- 1 year
- -24.67%
News
seekingalpha.com TransMedics: 2027 Setting Up To Be A Pivotal Year TransMedics Group is reiterated as a 'strong buy' due to compelling valuation and significant upside potential tied to multi-organ platform expansion. TMDX's 2027 catalysts include ENHANCE Heart,…
zacks.com TransMedics (TMDX) Just Reclaimed the 200-Day Moving Average TransMedics (TMDX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, TMDX broke through the 200-day moving average, which suggests a…
seekingalpha.com TransMedics: Growth Is Accelerating Again And 2027 Looks Promising TransMedics Group Inc. demonstrates accelerating revenue growth, improved service margins, and market share gains in the recent quarter. TransMedics raised full-year revenue guidance to $764-774…
fool.com TransMedics: 3 Key Takeaways for Long-Term Investors TransMedics raised 2026 revenue guidance to $764 million to $774 million. Third-quarter revenue reached $203 million, up 41% year over year.
benzinga.com UBS Maintains Neutral on TransMedics Group, Raises Price Target to $88 UBS analyst Patrick Wood maintains TransMedics Group (NASDAQ:TMDX) with a Neutral and raises the price target from $77 to $88.
zacks.com TransMedics (TMDX) Just Flashed Golden Cross Signal: Do You Buy? TransMedics (TMDX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, TMDX broke through the 20-day moving average, which suggests a…
zacks.com TransMedics (TMDX) Recently Broke Out Above the 50-Day Moving Average From a technical perspective, TransMedics (TMDX) is looking like an interesting pick, as it just reached a key level of support. TMDX recently overtook the 50-day moving average, and this suggests a…
marketbeat.com TransMedics Group Q3 Earnings Call Highlights TransMedics Group NASDAQ: TMDX raised its full-year revenue outlook after reporting record third-quarter revenue and transplant case volume, as gains in its liver and heart businesses helped offset a…
benzinga.com Needham Maintains Buy on TransMedics Group, Raises Price Target to $110 Needham analyst Mike Matson maintains TransMedics Group (NASDAQ:TMDX) with a Buy and raises the price target from $106 to $110.
benzinga.com Canaccord Genuity Maintains Buy on TransMedics Group, Raises Price Target to $120 Canaccord Genuity analyst Jason Mills maintains TransMedics Group (NASDAQ:TMDX) with a Buy and raises the price target from $95 to $120.
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Obsidian Therapeutics (NASDAQ:OBX) stock increased by 27.7% to $12.26 during Friday's regular session. The company's market cap stands at $593.0 million. TransMedics Group (NASDAQ:TMDX)…
schaeffersresearch.com Unusual Options Volume Report: 3 Stocks Moving After Earnings Three stocks are seeing unusual options activity following their quarterly earnings reports: DraftKings Inc (NASDAQ:DKNG), TransMedics Group Inc (NASDAQ:TMDX), and Omada Health Inc (NASDAQ:OMDA).
benzinga.com Moderna, JFrog, TransMedics, Ubiquiti And Other Big Stocks Moving Higher On Friday U.S. stocks rose, Nasdaq gained ~400 points. Moderna jumped 9.1% on strong Q3 results and higher FY26 guidance; other stocks rallied on results and deals.
zacks.com TransMedics (TMDX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates While the top- and bottom-line numbers for TransMedics (TMDX) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics…
seekingalpha.com TransMedics Group, Inc. (TMDX) Q3 2026 Earnings Call Transcript TransMedics Group, Inc. (TMDX) Q3 2026 Earnings Call Transcript
zacks.com TransMedics (TMDX) Q3 Earnings and Revenues Surpass Estimates TransMedics (TMDX) came out with quarterly earnings of $0.51 per share, beating the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.66 per share a year ago.
benzinga.com TransMedics Group Raises FY2026 Sales Guidance from $737.000M-$757.000M to $750.000M-$760.000M vs $743.798M Est TransMedics Group (NASDAQ:TMDX) raises FY2026 sales outlook from $737.000 million-$757.000 million to $750.000 million-$760.000 million vs $743.798 million estimate.
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers TransMedics Group (NASDAQ:TMDX) stock rose 17.6% to $81.16 during Thursday's after-market session. The company's market cap stands at $2.5 billion. The company's, Q3 earnings came out today.- benzinga.com TransMedics Gr Q3 Adj. EPS $0.51 Beats $0.29 Estimate, Sales $203.005M Beat $177.584M Estimate TransMedics Gr (NASDAQ:TMDX) reported quarterly earnings of $0.51 per share which beat the analyst consensus estimate of $0.29 by 75.86 percent. This is a 23.88 percent decrease over earnings of…
prnewswire.com TransMedics Reports Third Quarter 2026 Financial Results Strong Revenue Generation Drives Increase in Full-Year 2026 Guidance; Recent Progress Positions Company for Continued Growth with Several Near- and Mid-Term Catalysts ANDOVER, Mass., Nov. 5, 2026…
zacks.com Reasons to Retain TransMedics Stock in Your Portfolio for Now TMDX's OCS technology, robust pipeline and global expansion support growth prospects, but margin pressures and rising investments remain key concerns.
zacks.com What Analyst Projections for Key Metrics Reveal About TransMedics (TMDX) Q3 Earnings Looking beyond Wall Street's top-and-bottom-line estimate forecasts for TransMedics (TMDX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for…
businesswire.com TMDX Investors Have Opportunity to Join TransMedics Group, Inc. Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $TMDX--TMDX Investors Have Opportunity to Join TransMedics Group, Inc. Fraud Investigation with SBS Law.
prnewswire.com TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) ANDOVER, Mass., Oct. 30, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with…
prnewswire.com TransMedics to Present at Upcoming Investor Conferences ANDOVER, Mass., Oct. 29, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with…
globenewswire.com TransMedics selects Gogo Galileo HDX for nationwide organ transport fleet Reliable, high-performance connectivity will support time-critical transport and monitoring of donor organs for transplants aboard 22 Embraer Phenom 300E aircraft Reliable, high-performance…
prnewswire.com TransMedics to Report Third Quarter 2026 Financial Results on November 5, 2026 ANDOVER, Mass., Oct. 22, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with…
gurufocus.com A Look at TransMedics Group Inc (TMDX) After 3.1% Decline -- GF Value $160.75 vs Price $72.40 On October 21, 2026, TransMedics Group Inc (TMDX) shares fell by 3.1%, bringing the current price to $72.40. This decline is notable within a 52-week range of $
benzinga.com Canaccord Genuity Maintains Buy on TransMedics Group, Lowers Price Target to $94 Canaccord Genuity analyst Jason Mills maintains TransMedics Group (NASDAQ:TMDX) with a Buy and lowers the price target from $95 to $94.
benzinga.com Barclays Initiates Coverage On TransMedics Group with Overweight Rating, Announces Price Target of $120 Barclays analyst Christopher Pasquale initiates coverage on TransMedics Group (NASDAQ:TMDX) with a Overweight rating and announces Price Target of $120.- benzinga.com TransMedics Group Appoints Fernando Araujo CFO, Effective Sept. 21; Reaffirms FY26 Revenue Range $737M - $757M TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), the global leader in portable warm perfusion for donor organs for transplantation, today announced the appointment of Fernando Araujo as Chief…
benzinga.com TD Cowen Reiterates Buy on TransMedics Group, Maintains $120 Price Target TD Cowen analyst Joshua Jennings reiterates TransMedics Group (NASDAQ:TMDX) with a Buy and maintains $120 price target.
benzinga.com UBS Maintains Neutral on TransMedics Group, Lowers Price Target to $77 UBS analyst Patrick Wood maintains TransMedics Group (NASDAQ:TMDX) with a Neutral and lowers the price target from $80 to $77.- benzinga.com Piper Sandler Reiterates Overweight on TransMedics Group, Lowers Price Target to $100 Piper Sandler analyst Matt O'Brien reiterates TransMedics Group (NASDAQ:TMDX) with a Overweight and lowers the price target from $120 to $100.
benzinga.com SpaceX, Teradata, Pinterest And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session U.S. stock futures mixed, Dow up 100 points. SpaceX stock falls 10.3% after reporting strong Q2 revenue but a loss. Other stocks also decline.
benzinga.com TransMedics Group Raises FY2026 Sales Guidance from $727.000M-$757.000M to $737.000M-$757.000M vs $732.700M Est TransMedics Group (NASDAQ:TMDX) raises FY2026 sales outlook from $727.000 million-$757.000 million to $737.000 million-$757.000 million vs $732.700 million estimate.- benzinga.com TransMedics Gr Q2 Adj. EPS $0.44 Misses $0.47 Estimate, Sales $189.948M Beat $183.635M Estimate TransMedics Gr (NASDAQ:TMDX) reported quarterly earnings of $0.44 per share which missed the analyst consensus estimate of $0.47 by 6.38 percent. This is a 52.17 percent decrease over earnings of…
- benzinga.com Needham Maintains Buy on TransMedics Group, Lowers Price Target to $106 Needham analyst Mike Matson maintains TransMedics Group (NASDAQ:TMDX) with a Buy and lowers the price target from $142 to $106.
- benzinga.com Evercore ISI Group Maintains Outperform on TransMedics Group, Lowers Price Target to $90 Evercore ISI Group analyst Daniel Markowitz maintains TransMedics Group (NASDAQ:TMDX) with a Outperform and lowers the price target from $100 to $90.
- benzinga.com TD Cowen Reiterates Buy on TransMedics Group, Maintains $120 Price Target TD Cowen analyst Joshua Jennings reiterates TransMedics Group (NASDAQ:TMDX) with a Buy and maintains $120 price target.
- benzinga.com Stifel Maintains Hold on TransMedics Group, Raises Price Target to $80 Stifel analyst Tom Stephan maintains TransMedics Group (NASDAQ:TMDX) with a Hold and raises the price target from $75 to $80.
benzinga.com 7 Health Care Stocks With Whale Alerts In Today's Session - benzinga.com Stifel Maintains Hold on TransMedics Group, Lowers Price Target to $75 Stifel analyst Tom Stephan maintains TransMedics Group (NASDAQ:TMDX) with a Hold and lowers the price target from $85 to $75.
- benzinga.com If You Invested $1000 In TransMedics Group Stock 5 Years Ago, You Would Have This Much Today
- benzinga.com Canaccord Genuity Maintains Buy on TransMedics Group, Lowers Price Target to $124 Canaccord Genuity analyst William Plovanic maintains TransMedics Group (NASDAQ:TMDX) with a Buy and lowers the price target from $152 to $124.
- benzinga.com TD Cowen Maintains Buy on TransMedics Group, Lowers Price Target to $120 TD Cowen analyst Joshua Jennings maintains TransMedics Group (NASDAQ:TMDX) with a Buy and lowers the price target from $190 to $120.
- benzinga.com Stifel Maintains Hold on TransMedics Group, Lowers Price Target to $85 Stifel analyst Thomas Stephan maintains TransMedics Group (NASDAQ:TMDX) with a Hold and lowers the price target from $130 to $85.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session - benzinga.com Piper Sandler Maintains Overweight on TransMedics Group, Lowers Price Target to $120 Piper Sandler analyst Matt O'Brien maintains TransMedics Group (NASDAQ:TMDX) with a Overweight and lowers the price target from $160 to $120.
- benzinga.com Needham Maintains Buy on TransMedics Group, Lowers Price Target to $142 Needham analyst Mike Matson maintains TransMedics Group (NASDAQ:TMDX) with a Buy and lowers the price target from $174 to $142.